In the DEG-ESCC dataset, six compounds were identified: the MEK inhibitors “PD-0325901”, “selumetinib”, and “trametinib”, the ALK inhibitors “NVP-TAE684”, and PI3K inhibitor “wortmannin”, and the IGF-1 receptor inhibitor “BMS-536924” (Supplementary Figure S7a). This evidence concerns the gene MAP2K7 and esophageal squamous cell carcinoma.